A method of targeting to the synovial tissue biodegradable drug delivery compositions or morselizing biodegradable drug delivery compositions are described. The biodegradable drug composition comprises a triblock copolymer containing a polyester and a polyethylene glycol and a diblock copolymer containing a polyester and an end-capped polyethylene glycol, as well as at least one pharmaceutically active principle is disclosed.

A functional water containing a polyfunctional amine and/or a salt thereof as a functional component, wherein the total content of water, the polyfunctional amine, and the salt of the polyfunctional amine is 95% by weight or more. The polyfunctional amine is at least a specific polyamine, a polymer having a structural unit derived from a specific cyclic amine, or a polymer having a structural unit derived from a specific unsaturated amine. The total content of the polyfunctional amine and/or salt thereof is preferably 0.0001 to 10000 ppm by weight. The functional water has functions including freshness-keeping for foods, aging of foods, antisepsis, deodorization, adjustment of plant growth, life extension for cut flowers, flowering control for cut flowers, pest control, pest repellence, improvement of bowel movement, reduction of fecal odor, reduction of blood pressure, increase of body temperature, improvement of the intraoral environment, prevention of halitosis, and prevention of body odor.

A topical supplement composition. The topical supplement composition includes one or more vitamins, minerals, or other nutrients, in combination with one or more suitable transdermal carriers. The topical supplement composition delivers vitamins, minerals or other nutrients via transdermal application from an individual's skin to the individual's bloodstream.

A topical supplement composition. The topical supplement composition includes one or more vitamins, minerals, or other nutrients, in combination with one or more suitable transdermal carriers. The topical supplement composition delivers vitamins, minerals or other nutrients via transdermal application from an individual's skin to the individual's bloodstream.

The present invention relates to carbamoyl phenylalaninol compounds and methods of using the same to treat disorders.

A composition of food or therapeutic and other substances for administration as a cloud of droplets, the cloud comprising readily-soluble droplets having a median size range of approximately 3 microns to approximately 20 microns, or 5 microns to 10 microns, or 6 microns to 10 microns, for introduction to an animal via an ortho-nasal or retro-nasal route. Agonists or antagonists may include one or more of the following: sodium iodide, sodium chloride, magnesium chloride, capsaicin, piperine, linalool, ground cinnamon, a cannabinoid, pimento, onion, clove, thyme, ginger, menthol, or TRPV antagonists, and chocolate, Irish cream, caramel, lemon, lime, mango, raspberry, watermelon, blueberry, strawberry, mint, popcorn, meat, Resolvin D2 or nicotine. Devices for delivering compositions as an aerosol are described.

A precursor composition for the preparation of a dialysis fluid, the precursor composition comprising at least a glucose component, an acid component, and an amino acid component, wherein the amino acid component comprises Valine, Isoleucine and Leucine.

Disclosed herein are stabilized powder and aqueous formulations comprising a phospholipid comprising omega fatty acid and a micelle-forming surfactant. In one embodiment, the formulation further comprises a water soluble reducing agent, and/or a metal chelator, and/or a metal bisulfite reducing agent, or combinations thereof, wherein the formulation remains substantially clear and stable when stored at or below room temperature for a period of at least 6 months or at least 12 months; and methods for preparing these formulations.

The present invention relates generally to 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl}-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl}-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of X-linked hypophosphatemic rickets (XLH), autosomal dominant hypophosphatemic rickets (ADHR), autosomal recessive hypophosphatemic rickets (ARHR), tumor-induced osteomalacia, post-renal transplant hypophosphatemia, epidermal nevus syndrome, osteoglophonic dysplasia or McCune-Albright syndrome.

Described are methods for treating or preventing IBS in subjects by administering molybdenum or a salt thereof to subjects having or prone of getting IBS. The molybdenum has been shown to treat or prevent IBS in subjects administered this agent when compared to reference subjects not administered molybdenum.